©2022 Stanford Medicine
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Trial ID: NCT02299635
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)
PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
- Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
evidence of a) metastatic or b) locally recurrent advanced disease that is not
amenable to resection or radiotherapy with curative intent.
- Availability of an original diagnostic tumor tissue or the most recent metastatic
tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
Notch receptors genomic profiling
- Known brain metastases.
- Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305